Kairos Pharma Shares Set to Reverse Split on Tuesday, September 1st (NYSEAMERICAN:KAPA)

Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) shares are going to reverse split on the morning of Tuesday, September 1st. The 1-7 reverse split was recently announced. The number of shares owned by shareholders will be adjusted after the closing bell on Monday, August 31st.

Kairos Pharma Price Performance

NYSEAMERICAN KAPA traded down $0.06 during trading on Monday, hitting $0.23. The company’s stock had a trading volume of 1,701,340 shares, compared to its average volume of 660,022. Kairos Pharma has a fifty-two week low of $0.22 and a fifty-two week high of $2.11. The business’s 50 day simple moving average is $0.35 and its 200-day simple moving average is $0.49.

Kairos Pharma (NYSEAMERICAN:KAPA) last posted its quarterly earnings data on Wednesday, August 12th. The company reported ($0.06) earnings per share (EPS) for the quarter. As a group, equities analysts expect that Kairos Pharma will post -0.37 EPS for the current fiscal year.

Institutional Investors Weigh In On Kairos Pharma

A hedge fund recently bought a new position in Kairos Pharma stock. XTX Topco Ltd bought a new position in Kairos Pharma, Ltd. (NYSEAMERICAN:KAPA) in the second quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 62,746 shares of the company’s stock, valued at approximately $44,000. XTX Topco Ltd owned about 0.31% of Kairos Pharma at the end of the most recent reporting period.

About Kairos Pharma

Kairos Pharma (NYSEAMERICAN:KAPA) is a clinical‐stage biopharmaceutical company focused on developing small‐molecule therapies to treat genetic diseases caused by nonsense mutations. The company’s proprietary platform leverages targeted ribosomal modulation to promote readthrough of premature stop codons, with the goal of restoring production of full‐length functional proteins. Kairos Pharma’s pipeline includes multiple programs in preclinical and early clinical development for rare pediatric and orphan indications.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Kairos Pharma brings together a multidisciplinary team of researchers and clinicians dedicated to translating its technology into potential therapeutics.